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EORTC (30885) randomised phase III study with recombinant interferon 
alpha and recombinant interferon alpha and gamma in patients with 
advanced renal cell carcinoma
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10 x  106 IU m~2s.c. twice weekly in arm A and the same dose of rlP'N-a combined with rIFN-y
Summary In the treatment of renal cell carcinoma both complete (CRs) and partial remissions (PRs) have 
been obtained using recombinant (r) interferon alpha (IFN-oc), with response rates ranging from 0 to 31% 
(mean 16%). rIFN-y is a potent immunostimulating agent, but the clinical experience of its use is limited and 
results are conflicting. In a phase II study with the combination of rIFN-«jc (Boehringer Ingelheim) and 
rIFN-y (Genentech, supplied by Boehringer Ingelheim) in 31 eligible patients, a response rate o f 25% was 
recorded. Based on this observation a randomised phase III study was initiated to investigate the possible 
advantage o f the addition rIFN-y to rIFN-a2C treatment. Treatment consisted of rIFN-a2c 
30 fig m -2 =
100 ng m~2 =  2 x  106 IU m -2 in arm B. Eligibility criteria included documented progression of disease; 
patients with bone lesions only and overt central nervous system metastases were excluded. Between November 
1988 and September 1990, 102 patients were entered into the study. An interim analysis showed a response in 
7/53 (13%) patients (two CRs and five PRs) in the rIFN-oc2c monotherapy arm and in 2/45 (4%) (one CR and 
one PR) patients in the combination arm. This difference was not statistically significant (P =  0.17). The 
probability o f missing an eventual 10% advantage for the combination is 0.001. The numbers are insufficient 
to rule out a negative effect o f the addition of rIFN-y. The dose intensity of IFN-a2c for the two treatment 
arms was the same. The addition o f rIFN-y does not improve the response rate of rIFN-a2o monotherapy. A 
possible detrimental effect cannot be excluded.
Keywords: renal cell carcinoma; interferon alpha; interferon gamma.
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Patients with renal cell carcinoma (RCC) currently have few 
therapeutic options once the disease has become metastastic.
Approximately 25% of such patients have metastatic disease 
at the time of first presentation (Ritchie et al., 1983). The 
median survival for these patients is, independent of treat­
ment, 6 -1 2  months (De Forges et al., 1988). Spontaneous 
regression of metastases after tumour nephrectomy occurs in 
less than 1% (Montie, 1977). Treatment with hormones and 
chemotherapy, both single agent and combination, has no 
proven impact on survival (Harris et al., 1983; Yagoda and 
Bander, 1989). Several forms of immunotherapy have been 
applied, resulting in a limited number o f sometimes durable et al., 1987). The 
responses (McCune, 1983). Interferon-alpha (IFN-a) is most disappointing (Kurzrock
Modification o f the host response is frequently restricted to 
a narrow dose range, and in a recent study optimal modula­
tion by rIFN-y has been found in the low dose range 
(lOOjxgm-2) (Maluish et al., 1988). Against this background, 
the findings of Aulitzky et al. (1989) are interesting. They 
observed a 30% response rate (two CRs, four PRs) in 16 
patients treated with 100 fxg IFN-y (Genentech) s.c. once a 
week.
The combination of IFN-a and IFN-y has ben explored on 
the basis o f in vitro observations indicating a synergism 
between rIFN-y and rIFN-a (Czarniecki et a l 1984; Hubbell
far are, however, 
Foon et al.,
extensively used in the treatment of advanced RCC, both the 
natural and recombinant(r) forms. Most studies have pro­
vided evidence for modest but reproducible anti-tumour 
activity in advanced RCC (Goldstein and Laslo, 1986; 
Krown, 1987; Sarna et al., 1987; Muss, 1988, Buzaid and 
Todo, 1989; Horoszewski and Murphy, 1989). The response 
rates recorded from adequate trials (i.e. more than 20 eligible 
patients and a dose o f IFN-a of more than 3 x  106 U day-1, 
n =431) vary from 5 to 26% (mean 17%; 2% CR and 15% 
PR).
Experience with rIFN-y in renal cell carcinoma is limited 
and, with a few exceptions, disappointing (Rinehart et al..
; Quesada et al., 1987; Garnick et al., ; Otto et al..
1988; Aulitzky et al., Bruntsch et al., 1990). Little
information is available about the optimal dose, schedule and 
route o f IFN-y administration.
Quesada et al., 1988; Ernstoff et al., 1990). De Mulder and
irs et a l 1988; De Mulder et a i, 1990)co-workers
studied the efficacy of the combination of an escalating dose
-a2c (6 fig m - 2 =  2 x 106 U m " 2 starting dose) and a 
fixed low dose of rIFN-y (100 fig m ~2 =  2 x  106 m-2) twice 
weekly subcutaneously in patients with advanced progressive 
renal cell carcinoma. The overall response rate was 26% (two 
CRs, six PRs). The maximal tolerated dose of IFN-a2c was 
30 fig m “ 2 (6 - 36 figm “2). The feasibility and efficacy of this 
approach was proven in the treatment of a second cohort of 
patients (De Mulder et a l, 1991). In view of these data, an 
EORTC randomised study was initiated to determine if the 
addition of rIFN-y has any impact on the response rate and 
survival of patients with advanced metastatic renal cell car­
cinoma.
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Patients and methods
Trial design
The study was designed as a randomised phase III trial with
IFN-oc and IFN-y in RCC
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were available in each arm in order to ensure that continu­
ation of the trial was ethical. After checking all eligibility 
criteria, the randomisation was centrally performed at the 
EORTC Data Center. Patients were stratified according to 
institution and performance status. The study was performed 
according to good clinical practice guidelines, which included 
the verification o f all items given on the forms with the 
source documents. The main end points of the study were the 
comparison of the two treatments arms regarding response 
rate, time to response, response duration, survival and 
tolerance.
bilirubin, and gamma-glutamyl transferase. Total protein and 
subtractions, cholesterol, triglycerides and interferon
antibodies were monitored
graphy was repeated
every 
when indicated.
4 weeks. Electrocardio-
Tumours were
measured every 4 weeks with standard radiographic, com­
puterised tomographic or ultrasonographic techniques as ap­
propriate.
Patient population
Patients with histologically proven renal cell carcinoma with 
metastatic measurable or evaluable disease were considered 
for the study if they met the following criteria: age 18-75  
years; no prior chemo- and or immunotherapy; prior hor­
monal treatment was allowed; there should have been proven
Evaluation criteria
The criteria for measurability o f disease were according to 
the EORTC Data Center procedures manual (van Oosterom 
et al., 1993). Nodes smaller than 2 cm and liver metastases 
smaller than 3 cm in diameter were not considered to be 
measurable or evaluable. Complete remission (CR) was 
defined as the disappearance of all clinical evidence of 
tumour for a minimum of 4 weeks. Partial remission (PR) 
was defined as a 50% or greater decrease in the sum of the 
products of the perpendicular diameters of all measurable
progression, especially after a recent nephrectomy; World lesions, without simultaneous increase in the size of any
Health Organization (WHO) performance status 0 -1 ; ade­
quate haematological status, renal and liver function; normal 
serum calcium level; no concurrent serious medical illness 
(active infections, significant cardiac disease) or second 
malignancies except adequately treated basal cell carcinoma 
of the skin or cone biopsied carcinoma in situ of the cervix; 
no history o f seizure disorders or signs of central nervous 
system metastases; life expectancy of at least 3 months; 
absence o f a lipoprotein disorder. Concomitant medication 
with corticosteroids or vasodilators was not allowed. All 
patients gave their written or witnessed informed consent.
Treatment regimen
rIFN-a2c and rIFN-7 (Genentech) were supplied by Boeh­
ringer Ingelheim (Alkmaar, The Netherlands) and provided 
as a sterile lyophilised powder. The powder contained 15 jug 
of IFN-a2c with a degree of purity o f > 98%  and a specific 
activity of 4.4 x  106 IU 15 ¡ig~l based on the NIH IFN-a 
standard G0-23-901-527 for rIFN-a or 150 fig of IFN-y with 
a specific activity of 2 x 107 IU mg-1 protein, based on the 
NIH IFN-y standard Gg23-901-350. The freeze-dried prepar­
ations were reconstituted with 1 ml of sterile water immedi­
ately before use to yield rIFN-a2c and rIFN-Y concentrations 
o f 5 x  106 IU ml" 1 and 10 x  106 IU m l-' respectively.
Injections were given subcuteneously twice a week on an 
out-patient basis, although it was recommended that the first 
injection be given during a brief stay in hospital. Treatment 
arm A consisted of rIFN-a2c monotherapy and arm B con­
sisted of the same dose of rIFN-a2e plus rlFN-Y- rIFN-Y was
existing lesion or development of new lesions, for a minimum 
of 4 weeks. Progressive disease (PD) was defined as a 25% or 
greater increase in the size of at least one existing lesion or 
the appearance of new lesions. SD was defined as a decrease 
of less than 50% or an increase of less than 25%. For CR 
and PR duration of response was measured from the day of 
the start of treatment until disease progression or death. A 
patient was evaluable for toxicity when at least 4 weeks’ 
treatment was given. A patient was evaluable for response 
when at least 8 weeks treatment was completed. However, all 
patients with PD, irrespective of the duration o f treatment, 
were included in the response analysis. In case of stable 
disease treatment was to be discontinued after 6 months. 
When a PR or CR was seen treatment was to be continued 
to 1 year from the date of CR/PR.
given at a dose of 100 fig m ~2 (2 X 106 IU m~2) and rIFN-a2c 
was given at a dose of 30 |u gm -2 (10 x 10f) IU m~2). In arm 
B the two IFNs were given at the same time at two different 
sites. In the case of WHO grade III — IV toxicity, treatment 
was discontinued until recovery, with a maximum delay in 
treatment of 14 days. In case o f recovery, IFN treatment was 
to be restarted with a reduction of the dose of rIFN-a2c of 
6 /Agm-2. If a dose reduction resulted in a dose below 
12jiigm“ 2 the patient went off study. In case of grade II 
haematological toxicity, this was followed every 2 weeks until 
stabilisation was observed.
Acetaminophen (500 mg) was routinely prescribed to 
alleviate side-effects. This treatment was started 4 h before 
the IFN injection and continued for 24-48  h thereafter.
Statistical methods
The expected response rate for the combination arm was 
25-30% ; the expected response rate for the monotherapy 
arm was between 15% and 20%. The minimal difference in 
response rate which was of practical interest was defined to 
be 15%. To detect such a difference at error rates a = 0.05 
and P — 0.20, 94 eligible and evaluable patients were required 
on each treatment. In order to ensure that continuation o f  
the trial was ethical, an interum analysis was planned after 
receipt of the data for the first 40 patients in each arm. The 
response rates were compared using a two-sided Fisher exact 
test. The duration of response and the duration of survival 
were estimated by the Kaplan-Meier technique and com­
pared using a two-sided log-rank test.
Results
Pretreatment and follow-up examinations
Pre-study evaluations included full medical history and
Between November 1988 and September 1990, 102 patients 
entered the study and were randomly assigned to treatment 
as follows: arm A, 54 patients; arm B, 48 patients. Four 
patients were ineligible, one on treatment A and three on 
treatment B: one patient had a second primary, one patient 
had no evaluable lesions and two patients started within 4 
weeks after tumour nephrectomy without documented pro­
gression of metastatic disease. Nine eligible patients were not 
evaluable for response.
Patient characteristics at entry are depicted in Table I and 
are well balanced in the two treatment groups. For the entire 
group, 68% were male and 43% had a WHO performance 
status of 0. Eighteen per cent of the patients started treat-
physical examination, tumour measurements, electrocardio- ment with the primary tumour in situ. Prior radiotherapy, 
gram, chest radiograph, white blood cell count, platelets and mainly on threatening bone lesions, was given in 10% of the
a complete chemistry profile. Four-weekly monitoring in­
cluded side-effects according to the WHO grading system, 
haematological status, urine analyses and biochemical 
measures: creatinine, alkaline phosphatase, aspartate amino­
transferase, alanine aminotransferase, lactate dehydrogenase,
patients. Lung metastases were present in almost all patients. 
In 27% lung was the only site of disease. Liver metastases 
alone or in combination with other sites were seen in 14%. 
The majority o f the patients had only one or two sites of 
disease (76%).
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Table I Patient characteristics at entry
IFN-a. IFN-a + IFN-y
No. of patients (n == 102) 54 48
Not eligible 1 3
Male - female 37:17 32:16
Median age (range) 55 (27-75) 58 (32-74)
Performance status
WHO 0 20“ 23
WHO 1 33 25
Prior treatment (n = 
Nephrectomy
: 98)
42 38
No nephrectomy 11 7
Radiotherapy 8 2
Hormonal treatment 0 1
Site o f disease
Lungs only 14 14
Lungs -1- primary 4 3
Lungs + nodes 3 4
Lungs + liver 3 3
Lungs + others 7 9
Liver + others 5 3
Number of sites
1 17 19
2 19 23
3 -6 16 9
> 5 0 1
Not evaluable for response 6 7
Tabic II Response to treatment in eligible patients
r IFN-a
i .  c
r IFN-a,r + IFN-y
CR 1 0
pCR 1 1
PR 5 1
SD 19 19
PD 22 20
Early death 2 3
Unknown 3 I
Total 53 45
Response rate 13 % 4% (P =0.17)
There were four mixed responses on monotherapy and three mixed 
responses on the combination which are included in the Table as PD.
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Treatment efficacy
Considering all eligible patients (98) entered into the trial, the 
response rates were as follows: rIFN-a2l. monotherapy, one 
CR, one pathological CR, live PRs and 19 no change (NC), 
overall 13%; rIFN-a2c 4- rIFN-Y, one pathological CR, one 
PR and 19 NC, overall 4% (Table II). This difference was 
not statistically significant at P = 0 .17  in favour of arm A. If 
a relevant difference in favour of the combination arm were 
10% and the expected response on the monotherapy were
15%, probability of missing this difference with the
observed results would be 0.001. Although the difference was 
not statistically significant, the numbers are inadequate to 
show true equivalence or to exclude a potential negative 
effect of the addition of interferon-Y, however this was not 
the purpose of our study. A mixed response was seen in four 
out of 53 patients in arm A and three out o f 45 in arm B. 
The median time to response among responders was 114 days 
(range 59 301 days) and the median response duration was 
60 , with seven of the nine responders having pro­
gressed. Based on an average follow-up of 1 year, the overall 
median survival was 43 weeks in arm A and 34 weeks in arm 
B (P —0.73) (Figure 1). The time to progression is given in 
Figure 2. When the patients with their primary in situ are 
excluded, the observed response rate was 7/42 (17%) for 
treatment arm A and 2/38 (5%) for arm B. The characteris­
tics of all responding patients are shown in Table III. Six out 
of nine responded in the lungs, however only in two patients 
was this the only site of disease. In two patients concomitant 
metastases in the liver disappeared during therapy. The sites 
with unmet •wase remained clinically unchanged.
Figure 1 Time to progression,
100
90
80
O'" 70
X? 60
15 50
CO
X ! 40
Ou.
CL 30
20
10
30885 March 94
N
52
45
O
33
28
Treatment 
IFN-cx 
IFN-a + IFN-y
Log-rank P= 0.73
1«|*< vrtr> 1 1
i
' * N r L
I
0 12 18
( 1 m
24
i i L i
30 36 42 48
i
54
(months)
Number of patients at risk 
52 29 14 7
45 23 10 5
4
4
2
3
1
1
1
1
0 IFN-a
1 IFN-a + IFN-y
Figure 2 Duration of survival.
Toxicity
Observed grade II and III toxicity is given in Table IV.
Side-effects were known to with
interferon treatment. The vast majority of the patients
and to a;ver, anorexia,
Two patients had cytological proof o f renal cell carcinoma in 
the enlarged node prior to the start o f treatment, 
discontinuation of treatment lymph node dissection was per­
formed. Pathological examination revealed no tumour and 
the patients are therefore considered as having a pathological
CR.
One possible explanation for the lack of response in the 
combination arm could be a difference in the dose intensity 
of rIFN-a,c in the two groups. However, dose intensity, dose 
reductions and delays were similar in the two arms. In both
arms 90% of the patients received 100% o f the intended dose There is no doubt that interferons can induce responses in
flu-like symptoms. There was no difference between the two 
treatment groups. One patient developed a WHO grade III 
thrombocytopenia, but fully recovered after discontinuation 
of treatment. The white blood count (WBC) was only mar­
ginally influenced, although in the combination arm three 
patients developed reversible WHO grade III leucopenia.
Discussion
of rIFN-a,,.. advanced renal cell carcinoma. The response percentage
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1
2
3
4
5
6
7
8
9
Table III Characteristics o f responding patients
Age Sex PS Site Size Response Comment
61 M 1 Lung
Liver
22 X 19 
10 x  10
PR
CR
41 M 0 Lung
Local
23 x  22 
29 X 29
CR
CR
49 M I Nodes 30 X 35 PR
46 M 0 Nodes 30 x  25 pCR
53 F 1 Lung
Bone
15 x  10 
15 x  15 
4 0 x 2 0
PR
NC
55 M 1 Lung
Liver
Bone
20 X 11 
13 X 16 
8 x 9  
4 0 x 4 0  
6 2 x 5 9  
Irradiated
CR
PR
NC
66 F 0 Lung 49 x  23
6 x 6
15 X 12 
17 x  16 
17 X 17
PR
65 M 0 Lung 23 x  20 
15 X 13 
18 x  15 
20 X 18
PR
66 F 0 Nodes 25 x  40 CR
Response duration (weeks)
PD in lungs and nodes, brain metastases. 
Dead due to malignant disease
102
PD supraclavicular node. CDF after lymph 
node dissection
PD lungs, brain metastases. Dead due 
to malignant disease
No vital tumour at surgery
PD initial sites. Dead due to malignant 
disease
68
PD lungs. After metastasectomy NED  
Brain metastases. After RT alive
PD brain metastases. Death due to 
malignant disease
PD initial sites. Dead due to malignant 
disease
After surgery only fibrosis and non-vital 
tumour was seen (necrosis)
45
192 +  
21
91
52
43
211 +
CDF, continuously disease free; NED, no evidence of disease; RT, radiotherapy.
Table IV Toxicity (WHO grade)
r IFN-a, v*» I r IFN-CL2C+  IFN-y
11 III I I IU
Platelets 1 1 0 0
WBC 7 0 6 3
Pulmonary 4 2 0 1
Fever 27 9 24 9
Cutaneous 2 0 3 0
Alopecia 1 0 3 0
Cardiac (rhythm) 4 1 4 0
Mucous 1 0 2 0
Nausea and vomiting 11 5 9 5
Neurotoxicity 0 0 0 1
Non-WHO 2 -3 3
Flu-like syndrome 16 16
Anorexia 21 19
Mood alterations 8 6
Fatigue 27 24
Headache 5 8
II, moderate, III, severe
obtained from pooled data is about 17% (Krown, 1987; 
Muss, 1988; Horoszewicz et a!., 1989; De Mulder et al., 
1991). Prognostic factors such as performance status, tumour 
volume, presence of bone metastases and disease-free interval 
are well recognised and are the main explanation for the 
variation in response observed in the various studies. There is 
no indication that the route of administration, schedule or 
the type of IFN-a is critical for the observed clinical results. 
Dose dependency is suggested but an adequate randomised 
study to address this question has never been performed.
observed in the literature. One should realise that these 
results were obtained with a relatively low dose of IFN-a 
(10 x 106 IU m ~ 2) and a twice-weekly schedule, again an 
indication that the regimen is not critical and that IFN-a 
given above a certain threshold is able to induce responses in 
sensitive tumours. A  remarkable finding was that in two 
patients an objective response in the liver was seen.
The main purpose o f the study was to study the relevance 
of the addition o f IFN -7, which was based both on labora­
tory observations as well as on the results of earlier studies. 
The results were very disappointing because only in two 
patients (4%) was an objective response observed and the 
study, initially planned as a randomised phase III study, was 
stopped after an interim analysis. As indicated before, the 
probability o f obtaining these results if a difference of 10% in 
favour of the combination was actually present is extremely 
low. Equivalence in outcome or even the inverse outcome, 
i.e. a potential adverse effect o f the combination, cannot be 
excluded with adequate power in view of the numbers in­
volved, but this was not the purpose of the study. There is no 
satisfactory explanation for this result. Patient characteristics 
of the two patient populations were similar and the likeli­
hood that this observation could have been made by chance 
is almost negligible. The mechanisms of action of IFN-a are 
very pleiotropic, and many mechanisms can be responsible 
for the observed anti-tumour effect. There are actions directly 
on the tumour such as an antiproliferative effect, and there 
are indications that the induction of 2',5'-oligoadenylate syn­
thetase is related with this potential (Grander et al., 1990). 
On the other hand, immunological properties such as the 
induction of natural killer activity and the enhancement of 
the expression o f antigens on the tumour might play a role. 
The mechanism of action as elucidated in hairy cell
Very low daily dosages, i.e. below 2 x  106 IU daily, are prob- leukaemia (Vedantham et a l, 1992), the carcinoid (Grander 
ably ineffective. Our own observation in a small group o f et al., 1990) and the observation that the addition of 20 mg
patients corroborates this experience (Geboers et al., 1988).
In the present multicentre study the activity of IFN-a is 
confirmed with an overall response rate o f 13%. When only 
patients without their primary tumour are analysed, the re­
sponse rate is 17%, which is consistent with the range
o f prednisone had no impact on the anti-tumour effect 
(Fossa et al., 1990) suggest a direct effect on the tumour cell. 
Interferon-gamma is considered a true immunomodulating 
agent, predominantly on macrophages, with few direct anti­
proliferative effects on tumour cells. The results with IFN-y
monotherapy are generally disappointing. The 30% response 
rate observed by Aulitzky et al. (1989), so far unconfirmed, 
applying an individually tailored dose of IFN-y based on 
parameters of immune stimulation such as neopterin excre­
tion, indicates the sensitivity of this disease depending on 
very specific requirements. The IFN-y dose used in the pre­
sent study was within the same range. One of the explana­
tions of the generally low response rate in combination
IFN-a and IFN-y in RCC
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studies could be the relatively low dose of IFN-a given in 
these studies (De Mulder et al., 1991). In the present study 
this explanation is unlikely in view of the almost identical 
dose intensity of IFN-a2c in the two treatment arms.
Based on these results, the combination of IFN-a and 
IFN-y in the dose and schedule described in this study can­
not be recommended. Our results confirm the limited activity 
of IFN-a monotherapy in this disease.
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